FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337161741> ?p ?o ?g. }

• W2337161741 abstract "Lymphangioleiomyomatosis (LAM) is a female predominant progressive and neoplastic disorder that leads to lung destruction and respiratory failure primarily in women. LAM is typically due to TSC2 mutations resulting in mTORC1 activation in proliferative smooth muscle-like cells in the lung. The female predominance of LAM suggests that estradiol contributes to disease development. Metabolomic profiling identified estradiol-enhanced prostaglandin biosynthesis signature in Tsc2-deficient cells, both in vitro and in vivo. Estradiol increased the expression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in prostaglandin biosynthesis, which was increased at baseline in TSC2-deficient cells, and was not affected by rapamycin treatment, but decreased by Torin 1 treatment and Rictor knockdown, associated with reduction of levels phospho-Akt (S473). Prostaglandin production was also increased in TSC2-deficient cells. In preclinical models, Celecoxib or aspirin treatment suppressed tumor progression. LAM patients had significantly higher serum prostaglandin levels than healthy women. 15-epi-lipoxin-A4 was identified in exhaled breath condensate from LAM subjects and was increased by aspirin treatment, indicative of functional COX-2 expression in the LAM airway. Targeting COX-2 and prostaglandin pathways may have therapeutic value in LAM and TSC-related diseases, and possibly in other conditions associated with mTOR-hyperactivation. Citation Format: Chenggang Li, Po-Shun Lee, Yang Sun, Xiaoxiao Gu, Erik Zhang, Chin-Lee Wu, Andrey Parkhitko, Neil Aurrichio, Tasha Morrison, John Blenis, Kai-Feng Xu, Elizabeth Petri Henske, Bruce Levy, David Kwiatkowski, Jane Yu. Aspirin inhibits cyclooxygenase 2-mediated prostaglandin production and tumorigenesisin a preclinical model of tuberous sclerosis complex. [abstract]. In: Proceedings of the AACR Special Conference: The Translational Impact of Model Organisms in Cancer; Nov 5-8, 2013; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(11 Suppl):Abstract nr B09." @default.
• W2337161741 created "2016-06-24" @default.
• W2337161741 creator A5010102166 @default.
• W2337161741 creator A5010157362 @default.
• W2337161741 creator A5010278316 @default.
• W2337161741 creator A5019076582 @default.
• W2337161741 creator A5033278380 @default.
• W2337161741 creator A5037431238 @default.
• W2337161741 creator A5045740849 @default.
• W2337161741 creator A5048152454 @default.
• W2337161741 creator A5048425784 @default.
• W2337161741 creator A5050132863 @default.
• W2337161741 creator A5060312338 @default.
• W2337161741 creator A5068118983 @default.
• W2337161741 creator A5085277849 @default.
• W2337161741 creator A5086852798 @default.
• W2337161741 creator A5089688533 @default.
• W2337161741 date "2014-11-01" @default.
• W2337161741 modified "2023-10-18" @default.
• W2337161741 title "Abstract B09: Aspirin inhibits cyclooxygenase 2-mediated prostaglandin production and tumorigenesisin a preclinical model of tuberous sclerosis complex" @default.
• W2337161741 doi "https://doi.org/10.1158/1557-3125.modorg-b09" @default.
• W2337161741 hasPublicationYear "2014" @default.
• W2337161741 type Work @default.
• W2337161741 sameAs 2337161741 @default.
• W2337161741 citedByCount "0" @default.
• W2337161741 crossrefType "proceedings-article" @default.
• W2337161741 hasAuthorship W2337161741A5010102166 @default.
• W2337161741 hasAuthorship W2337161741A5010157362 @default.
• W2337161741 hasAuthorship W2337161741A5010278316 @default.
• W2337161741 hasAuthorship W2337161741A5019076582 @default.
• W2337161741 hasAuthorship W2337161741A5033278380 @default.
• W2337161741 hasAuthorship W2337161741A5037431238 @default.
• W2337161741 hasAuthorship W2337161741A5045740849 @default.
• W2337161741 hasAuthorship W2337161741A5048152454 @default.
• W2337161741 hasAuthorship W2337161741A5048425784 @default.
• W2337161741 hasAuthorship W2337161741A5050132863 @default.
• W2337161741 hasAuthorship W2337161741A5060312338 @default.
• W2337161741 hasAuthorship W2337161741A5068118983 @default.
• W2337161741 hasAuthorship W2337161741A5085277849 @default.
• W2337161741 hasAuthorship W2337161741A5086852798 @default.
• W2337161741 hasAuthorship W2337161741A5089688533 @default.
• W2337161741 hasConcept C126322002 @default.
• W2337161741 hasConcept C134018914 @default.
• W2337161741 hasConcept C181199279 @default.
• W2337161741 hasConcept C185592680 @default.
• W2337161741 hasConcept C2776773979 @default.
• W2337161741 hasConcept C2777628954 @default.
• W2337161741 hasConcept C2777956040 @default.
• W2337161741 hasConcept C2779422105 @default.
• W2337161741 hasConcept C2779689624 @default.
• W2337161741 hasConcept C2780664492 @default.
• W2337161741 hasConcept C502942594 @default.
• W2337161741 hasConcept C55493867 @default.
• W2337161741 hasConcept C62478195 @default.
• W2337161741 hasConcept C71924100 @default.
• W2337161741 hasConcept C75217442 @default.
• W2337161741 hasConcept C86554907 @default.
• W2337161741 hasConcept C98274493 @default.
• W2337161741 hasConcept C98490376 @default.
• W2337161741 hasConceptScore W2337161741C126322002 @default.
• W2337161741 hasConceptScore W2337161741C134018914 @default.
• W2337161741 hasConceptScore W2337161741C181199279 @default.
• W2337161741 hasConceptScore W2337161741C185592680 @default.
• W2337161741 hasConceptScore W2337161741C2776773979 @default.
• W2337161741 hasConceptScore W2337161741C2777628954 @default.
• W2337161741 hasConceptScore W2337161741C2777956040 @default.
• W2337161741 hasConceptScore W2337161741C2779422105 @default.
• W2337161741 hasConceptScore W2337161741C2779689624 @default.
• W2337161741 hasConceptScore W2337161741C2780664492 @default.
• W2337161741 hasConceptScore W2337161741C502942594 @default.
• W2337161741 hasConceptScore W2337161741C55493867 @default.
• W2337161741 hasConceptScore W2337161741C62478195 @default.
• W2337161741 hasConceptScore W2337161741C71924100 @default.
• W2337161741 hasConceptScore W2337161741C75217442 @default.
• W2337161741 hasConceptScore W2337161741C86554907 @default.
• W2337161741 hasConceptScore W2337161741C98274493 @default.
• W2337161741 hasConceptScore W2337161741C98490376 @default.
• W2337161741 hasLocation W23371617411 @default.
• W2337161741 hasOpenAccess W2337161741 @default.
• W2337161741 hasPrimaryLocation W23371617411 @default.
• W2337161741 hasRelatedWork W1535310919 @default.
• W2337161741 hasRelatedWork W1571151195 @default.
• W2337161741 hasRelatedWork W1831445971 @default.
• W2337161741 hasRelatedWork W1969046280 @default.
• W2337161741 hasRelatedWork W1975645401 @default.
• W2337161741 hasRelatedWork W1978713285 @default.
• W2337161741 hasRelatedWork W2039440310 @default.
• W2337161741 hasRelatedWork W2091998576 @default.
• W2337161741 hasRelatedWork W2121655277 @default.
• W2337161741 hasRelatedWork W2122900984 @default.
• W2337161741 hasRelatedWork W2148165857 @default.
• W2337161741 hasRelatedWork W2162767500 @default.
• W2337161741 hasRelatedWork W2172202139 @default.
• W2337161741 hasRelatedWork W2580159428 @default.
• W2337161741 hasRelatedWork W2783940258 @default.
• W2337161741 hasRelatedWork W2892374753 @default.
• W2337161741 hasRelatedWork W2895911020 @default.
• W2337161741 hasRelatedWork W3007384018 @default.
• W2337161741 hasRelatedWork W3044328919 @default.
• W2337161741 hasRelatedWork W53968717 @default.

• next